Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will FDA's nod for Millennium's subQ Velcade be a thorn in Onyx's side?

This article was originally published in Scrip

Executive Summary

With the US FDA's approval on 23 January of Millennium’s Velcade (bortezomib) for use as a subcutaneously administered drug, patients not only get more convenience and similar efficacy benefits against multiple myeloma and mantle-cell lymphoma as that demonstrated with the intravenous version of the drug, which has been on the US market for nearly a decade, but the new route of administration has been shown to have fewer adverse effects, said CEO Dr Deborah Dunsire.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts